IMNNHealthcare · BiotechnologyThe 4 Wall Street analysts covering Imunon, Inc. hold a median 12-month price target of $13 — +1115.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Imunon, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (95): Smaller than most of the companies we track.
Momentum (3): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IMNN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +1115.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Apr 2026 | Maxim Group | Initiates | Buy | $10 |
| 19 May 2025 | D. Boral Capital | Downgrade | Hold | — |
| 13 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 7 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 26 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 19 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 24 Jan 2025 | D. Boral Capital | Maintains | Buy | — |
| 19 Dec 2024 | D. Boral Capital | Maintains | Buy | — |
| 19 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Dec 2024 | D. Boral Capital | Maintains | Buy | — |
| 25 Nov 2024 | D. Boral Capital | Maintains | Buy | — |
| 11 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Nov 2024 | EF Hutton | Maintains | Buy | — |
| 31 Oct 2024 | EF Hutton | Maintains | Buy | — |
| 23 Sept 2024 | EF Hutton | Initiates | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMNN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Imunon, Inc. returned −79.9% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 78% of US stocks
Cheaper than 34% of US stocks
Cheaper than 66% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 4% of US stocks
Higher than 4% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Imunon, Inc. has a market value of $6.4M and an enterprise value of $9.6M.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: −$14.6M.
Free cash flow in the twelve months to 31 Mar 2026: −$15.1M, after $21K of capital spending.
Trailing P/E: −0.2×; forward P/E: −0.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Imunon, Inc. employs 20 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Imunon, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
IMUNON announced that Stacy Lindborg, Ph.D., will participate in upcoming investor conferences. The announcement identifies IMUNON as a clinical-stage biotechnology company developing DNA-mediated immunotherapies.
Why it matters — The conferences provide an upcoming opportunity for IMUNON to present to investors.
IMUNON entered into an Exchange Agreement converting $1.2 million of outstanding debt, plus accrued interest, into shares of its newly designated, non-convertible Series B Preferred Stock. The exchange reduces the original Note's outstanding debt by about 43% and involves no issuance of common stock or dilutive warrants.
Why it matters — IMUNON watchers would care because this debt-to-equity conversion reduces the company's outstanding debt without diluting common shareholders, potentially strengthening its balance sheet and providing efficient access to equity capital.
IMUNON presented an update on its IMNN-001 development program for newly diagnosed advanced ovarian cancer at its 2026 R&D Day, reviewing final Phase 2 overall survival results, supportive preliminary MRD study data and translational findings, the pathway to confirmatory readout in OVATION 3, and a testimonial from an OVATION 1 participant now 10 years from diagnosis.
Why it matters — The presentation frames IMNN-001's Phase 3 case around a 14.7-month overall survival signal, overcoming historical IL-12 safety barriers, and ahead-of-plan enrollment, offering IMNN watchers an update on the program's development progress.
Seeking Alpha published the transcript of Imunon, Inc.'s (IMNN) shareholder/analyst call, providing a record of the company's discussion with investors and analysts. The excerpt does not include details of the call's content.
Why it matters — The transcript gives IMNN watchers direct access to management's commentary and responses during the call, beyond the headline.
Imunon, Inc. announced that an independent Data Monitoring Committee recommended the ongoing Phase 2 MRD study of IMNN-001 continue without modification, following a favorable review of all safety data to date.
Why it matters — A recommendation to continue Phase 2 development without modification signals that safety data collected so far have been deemed satisfactory, supporting forward progress of IMNN-001.
The 4 Wall Street analysts covering Imunon, Inc. have a median 12-month price target of $13, with estimates ranging from $10 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Imunon, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Imunon, Inc. 24 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Imunon, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +1115.0% from the last close, and Ticker Nerd's factor model ranks Imunon, Inc. 24 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Imunon, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMNN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $25 over the next 12 months.
Imunon, Inc. returned -79.9% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Imunon Inc. is a clinical-stage biotechnology company focused on developing DNA-based immunotherapies and vaccines for difficult-to-treat diseases.
The most recent item we track (GlobeNewsWire, 8 Oct 2026): "IMUNON to Participate in Upcoming Investor Conferences". IMUNON announced that Stacy Lindborg, Ph.D., will participate in upcoming investor conferences. The announcement identifies IMUNON as a clinical-stage biotechnology company developing DNA-mediated immunotherapies.
Imunon Inc. is a clinical-stage biotechnology company focused on developing DNA-based immunotherapies and vaccines for difficult-to-treat diseases. The company’s current portfolio centers on proprietary non-viral DNA platforms designed to activate the body’s immune system at the site of disease, with applications in oncology and infectious diseases. Its lead program, IMNN-001, is being developed as a localized immunotherapy for advanced ovarian cancer, while its PlaCCine platform supports nucleic acid vaccine research for infectious disease targets. Imunon also advances additional preclinical and early-stage programs across solid tumors and viral indications. Headquartered in Lawrenceville, New Jersey, Imunon plays a specialized role in the biotechnology market by pursuing platform-based treatments that combine immunology, gene delivery, and cancer therapy research.
CEO Dr. Stacy R. Lindborg Ph.D. · 20 employees · United States · https://imunon.com
